Skip to main content

Table 2 Relationships between pretreatment thrombocytosis and clinicopathologic parameters.

From: Pretreatment thrombocytosis as an independent predictive factor for chemoresistance and poor survival in epithelial ovarian cancer

Parameters

 

Platelet counts (× 103/ mm3)

P

<  400 (n = 227)

≥ 400 (n = 53)

Age (years)

Mean ± SD

56.8 ± 11.9

55.9 ± 11.9

0.52

Hb (g/ dl)

Mean ± SD

12.1 ± 1.4

10.9 ± 1.7

<  0.0001

Microcytic hypochromic anemia

0.00090

 Present

12 (5.3%)

11 (20.8%)

 

 Absent

215 (94.7%)

42 (79.2%)

 

Primary treatment

0.0028

 PDS

177 (78.0%)

30 (56.6%)

 

 NAC

50 (22.0%)

23 (43.4%)

 

FIGO stage

0.0018

 I

82 (36.1%)

9 (17.0%)

 

 II

35 (15.4%)

4 (7.5%)

 

 III

84 (37.0%)

26 (49.1%)

 

 IV

26 (11.5%)

14 (26.4%)

 

Histologic subtype

0.034

 Serous

77 (33.9%)

28 (52.8%)

 

 Clear cell

70 (30.8%)

13 (24.5%)

 

 Others*

80 (35.3%)

12 (22.7%)

 

Operation achievement

0.00050

 Complete

178 (78.4%)

28 (52.8%)

 

 Optimal

36 (15.9%)

20 (37.7%)

 

 Suboptimal

13 (5.7%)

5 (9.5%)

 

Nonmalignant inflammatory condition

0.0022

 Present

7 (3.1%)

8 (15.1%)

 

 Absent

220 (96.9%)

45 (84.9%)

 

CA125 (U/ mL)

Mean ± SD

1233 ± 3012

3127 ± 5278

<  0.0001

  1.  *Endometorioid, mucinous, undifferentiated, or mixed type. Abbreviations: SD standard deviation, Hb hemoglobin, PDS primary debulking surgery, NAC neoadjuvant chemotherapy, FIGO International Federation of Gynecology and Obstetrics, TFI treatment-free interval